Journal of Antimicrobial Chemotherapy (2001) 47, 15-25
© 2001 The British Society for Antimicrobial Chemotherapy
In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial
a Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242; b Schering-Plough Research Institute, Kenilworth, NJ 07033, USA
The antimicrobial activity of evernimicin (formerly SCH 27899), a novel oligosaccharide antimicrobial of the everninomicin class, was evaluated against four groups of Gram-positive pathogens: (i) Streptococcus pneumoniae (n = 1452); (ii) methicillin- or oxacillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci (MR-CoNS; n = 1427); (iii) enterococci (n = 1517); and (iv) non-pneumococcal streptococci (n = 1388), using the Etest method at each study centre throughout Eastern and Western Europe, Scandinavia, South Africa, Turkey and North America. Comparative MICs were determined for a variety of reference compounds, including vancomycin, quinupristin/dalfopristin, chloramphenicol, penicillin, ampicillin, oxacillin, ceftriaxone and ciprofloxacin. Evernimicin was highly active against all strains tested, with MIC90 values 1.0 mg/L, ranging from 0.047 mg/L against S. pneumoniae to 1.0 mg/L against MRSA/MR-CoNS and enterococci. Compared with the reference agents, the MIC90 of evernimicin were lower against all species. Against MRSA and MR-CoNS the MIC90s of evernimicin, quinupristin/dalfopristin and vancomycin (the three most active agents) were 1.0, 1.5 and 3.0 mg/L, respectively. Against all species tested, the relative activities and spectra of these agents were: evernimicin > vancomycin > quinupristin/dalfopristin. The Etest proved to be reliable and reproducible, despite occasional interpretive difficulties caused by observer inexperience. Quality control results were excellent among the 33 participant sites. The results of this in vitro, multicentre, multinational study demonstrate that evernimicin possesses high antimicrobial activity against Gram-positive organisms that compares favourably with established antibacterial treatments and newer agents such as quinupristin/dalfopristin. Further clinical investigations of everninomicin class compounds appear warranted.
* Correspondence address. Suite A, 345 Beaver Kreek Center, North Liberty, IA 52317, USA. Tel: +1-319-665-3370; Fax: +1-319-665-3371; E-mail: ronald-jones{at}mikrongroup.com
Members of the Ziracin Susceptibility Testing Group are listed in the Acknowledgements.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Petsaris, F. Miszczak, M. Gicquel-Bruneau, A. Perrin-Guyomard, F. Humbert, P. Sanders, and R. Leclercq Combined Antimicrobial Resistance in Enterococcus faecium Isolated from Chickens Appl. Envir. Microbiol., May 1, 2005; 71(5): 2796 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Poulet, R. Veneziale, P. M. Vancutsem, P. Losco, K. Treinen, and R. E. Morrissey Ziracin-Induced Congenital Urogenital Malformations in Female Rats Toxicol Pathol, April 1, 2005; 33(3): 320 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Musher, J. G. Bartlett, and G. V. Doern A Fresh Look at the Definition of Susceptibility of Streptococcus pneumoniae to {beta}-Lactam Antibiotics Arch Intern Med, November 26, 2001; 161(21): 2538 - 2544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hallgren, H. Abednazari, C. Ekdahl, H. Hanberger, M. Nilsson, A. Samuelsson, E. Svensson, L. E. Nilsson, and t. Swedish ICU Study Group Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems J. Antimicrob. Chemother., July 1, 2001; 48(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|